Pregnancy outcome in women exposed to dopamine agonists during pregnancy: A pharmacoepidemiology study in EFEMERIS database

Archives of Gynecology and Obstetrics

Volumn 290, Issue 2, 2014, Pages 263-270

  Hurault Delarue, Caroline ^a   Montastruc, Jean Louis ^a   Beau, Anna Belle ^a   Lacroix, Isabelle ^a   Damase Michel, Christine ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Dopamine agonists; Outcome; Pregnancy; Psychomotor development

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PIRIBEDIL; QUINAGOLIDE;

ADULT; ARTERY DISEASE; ARTICLE; BIRTH DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DATABASE; FEMALE; FIRST TRIMESTER PREGNANCY; FRANCE; GESTATIONAL AGE; HUMAN; HYPERPROLACTINEMIA; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL EXPOSURE; PSYCHOMOTOR DEVELOPMENT; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VISUAL DISORDER;

ABORTION, SPONTANEOUS; ADULT; COHORT STUDIES; DATABASES, FACTUAL; DOPAMINE AGONISTS; FEMALE; FRANCE; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREMATURE BIRTH; RISK;

EID: 84904490637     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3210-z     Document Type: Article

References (17)

1. Kars M, Souverein PC, Herings RMC et al (2009) Estimated age- and gender-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94(8):2729-2734
2. Elbaz A, Bower JH, Maraganore DM et al (2002) Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55(1):25-31 (Pubitemid 34044099)
3. Sundström E, Kölare S, Souverbie F et al (1993) Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Brain Res Dev Brain Res 75(1):1-12 (Pubitemid 23265082)
4. Herlenius E, Lagercrantz H (2004) Development of neurotransmitter systems during critical periods. Exp Neurol 190(Suppl 1):S8-S21 (Pubitemid 39451785)
5. Lacroix I, Hurault C, Sarramon MF et al (2009) Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 65(8):839-846
6. Beck S, Wojdyla D, Say L et al (2010) The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Org 88(1):31-38
7. WHO health status statistics: morbidity. http://www.who.int/healthinfo/ statistics/indlowbirthweight/en/index.html. Accessed 17 Dec 2012
8. Les certificats de santé aux 8e jour, 9e mois et 24e mois - Drees - Ministère des Affaires sociales et de la Santé. http://www.drees.sante.gouv.fr/les-certificats-de-sante-aux-8e-jour-9e-mois-et- 24e-mois,7333.html. Accessed 18 Feb 2013
9. Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65(17):823-827 (Pubitemid 17123339)
10. Stalldecker G, Mallea-Gil MS, Guitelman M et al (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345-350
11. Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68(1):66-71 (Pubitemid 350243483)
12. Ricci E, Parazzini F, Motta T et al (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16(6):791-793 (Pubitemid 35278500)
13. Källen B, Olausson Otterblad P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20(2):209-214 (Pubitemid 40725070)
14. Turkalj I, Braun P, Krupp P (1982) Surveillance of bromocriptine in pregnancy. JAMA 247(11):1589-1591 (Pubitemid 12180080)
15. Estan L, Berenquer A, Martinez-Mir I, Rubio E, Morales-Olivas FJ (1993) Response to dopamine agonists of the rat isolated uterus. Gen Pharmacol 24:397-401 (Pubitemid 23103516)
16. Estan L, Martinez-Mir I, Rubio E, Morales-Olivas FJ (1988) Relaxant effect of dopamine on the isolated rat uterus. Naunyn Schmiedebergs Arch Pharmacol 338:484-488 (Pubitemid 19014454)
17. Gobello C (2006) Dopamine agonists, anti-progestins, antiandrogens, long-term-release GnRH agonists and anti-estrogens in canine reproduction: a review. Theriogenology 66:1560-1567